• Order to parcel locker

    Order to parcel locker
  • easy pay

    easy pay
  • Reduced price
Drug Compounding Pharmacies: Risks & Oversight Issues

Drug Compounding Pharmacies: Risks & Oversight Issues

9781628081763
661.44 zł
595.29 zł Save 66.15 zł Tax included
Lowest price within 30 days before promotion: 595.29 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
In light of the 2012 fungal meningitis outbreak, believed to have been caused by a contaminated compounded steroid injection, the regulation of human drug compounding has received significant attention. Drug compounding in its traditional form is the process of combining, mixing, or altering ingredients in order to create a medication for a particular patient. However, as illustrated by the entity that created the steroid medication linked with the meningitis outbreak, concerns have been raised about compounding pharmacies producing drugs on a larger scale. While drug compounding has historically been the focus of state governments through their regulation of pharmacies, questions have arisen regarding the extent the federal government can regulate the practice of compounding through the Food, Drug, and Cosmetic Act (FDCA). This book examines the FDAs regulation of drug compounding and discusses relevant legal authorities, and the potential limits to the FDAs authority to regulate human drug compounding.
Product Details
74281
9781628081763
9781628081763

Data sheet

Publication date
2013
Issue number
1
Cover
hard cover
Pages count
137
Dimensions (mm)
155.00 x 230.00
Weight (g)
386
  • Preface; Federal Authority to Regulate the Compounding of Human Drugs; FDAs Authority to Regulate Drug Compounding:: A Legal Analysis; State of Disarray:: How States Inability to Oversee Compounding Pharmacies Puts Public Health at Risk; Compounding Pharmacies, Compounding Risk; The New England Compounding Center & the Meningitis Outbreak of 2012:: A Failure to Address Risk to the Public Health; Selected Resources on Federal Oversight of Compounding Pharmacies; Index.
Comments (0)